KR860001876B1 - 헤테로고리 카르복사미드의 제조방법 - Google Patents

헤테로고리 카르복사미드의 제조방법 Download PDF

Info

Publication number
KR860001876B1
KR860001876B1 KR8200910A KR820000910A KR860001876B1 KR 860001876 B1 KR860001876 B1 KR 860001876B1 KR 8200910 A KR8200910 A KR 8200910A KR 820000910 A KR820000910 A KR 820000910A KR 860001876 B1 KR860001876 B1 KR 860001876B1
Authority
KR
South Korea
Prior art keywords
methyl
quinoline
carboxamide
dihydro
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
KR8200910A
Other languages
English (en)
Korean (ko)
Other versions
KR830009037A (ko
Inventor
에릭소 에드가
브리트-마리 샌드베르그 에바
조한 토브존 스탈핸드스키 라스
Original Assignee
피. 이. 치버그, 보 크리스토퍼 올슨
악티에보라케트 레오
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피. 이. 치버그, 보 크리스토퍼 올슨, 악티에보라케트 레오 filed Critical 피. 이. 치버그, 보 크리스토퍼 올슨
Publication of KR830009037A publication Critical patent/KR830009037A/ko
Application granted granted Critical
Publication of KR860001876B1 publication Critical patent/KR860001876B1/ko
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
KR8200910A 1981-03-03 1982-03-03 헤테로고리 카르복사미드의 제조방법 Expired KR860001876B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8106594 1981-03-03
GB8106594 1981-03-03

Publications (2)

Publication Number Publication Date
KR830009037A KR830009037A (ko) 1983-12-17
KR860001876B1 true KR860001876B1 (ko) 1986-10-24

Family

ID=10520089

Family Applications (1)

Application Number Title Priority Date Filing Date
KR8200910A Expired KR860001876B1 (ko) 1981-03-03 1982-03-03 헤테로고리 카르복사미드의 제조방법

Country Status (21)

Country Link
US (2) US4547511A (https=)
EP (1) EP0059698B1 (https=)
JP (1) JPS57171975A (https=)
KR (1) KR860001876B1 (https=)
AT (1) ATE15798T1 (https=)
AU (1) AU547849B2 (https=)
CA (1) CA1182455A (https=)
DE (1) DE3266464D1 (https=)
DK (1) DK157859C (https=)
ES (1) ES8400409A1 (https=)
FI (1) FI79532C (https=)
GR (1) GR76073B (https=)
HK (1) HK38689A (https=)
HU (1) HU186909B (https=)
IE (1) IE52670B1 (https=)
IL (1) IL65028A (https=)
NO (1) NO163130C (https=)
NZ (1) NZ199888A (https=)
PH (1) PH18520A (https=)
PT (1) PT74512B (https=)
ZA (1) ZA821210B (https=)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3269753A (en) * 1964-08-31 1966-08-30 Data Man Inc Bookkeeping unit
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US4400017A (en) * 1981-03-04 1983-08-23 Pendergrass Russell G Integrated budget and check record book
US4650804A (en) * 1984-03-30 1987-03-17 Fujisawa Pharmaceutical Co., Ltd. Quinolizinone compounds and pharmaceutical composition comprising the same, useful as anti-ulcerative and anti-allergic agents
DE3420116A1 (de) * 1984-05-30 1985-12-05 Bayer Ag, 5090 Leverkusen Immunstimulierende mittel
US4786644A (en) * 1987-11-27 1988-11-22 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinolinecarboxamide
IT1228293B (it) * 1989-02-06 1991-06-07 Angeli Inst Spa Benzoderivati di composti eterociclici contenenti azoto.
SE8902076D0 (sv) * 1989-06-09 1989-06-09 Pharmacia Ab Derivatives of quinoline-3-carboxanilide
US5310913A (en) * 1989-06-09 1994-05-10 Kabi Pharmacia Aktiebolag Derivatives of quinoline-3-carboxanilide
SE9000624D0 (sv) * 1990-02-22 1990-02-22 Pharmacia Ab New use
US5691350A (en) * 1990-02-22 1997-11-25 Kabi Pharmacia Ab Use of linomide for treatment of retrovirus infections specifically HIV infections
US5504092A (en) * 1990-03-27 1996-04-02 Pharmacia Ab Use of Linomide to increase hemopoietic cell precursors
SE9001111D0 (sv) * 1990-03-27 1990-03-27 Pharmacia Ab Supportive use
JPH06501465A (ja) * 1990-09-07 1994-02-17 シェリング・コーポレーション 抗ウイルス化合物
US5378694A (en) * 1990-09-07 1995-01-03 Schering Corporation Acyl and alkoxy substituted quinolines
EP0549729B1 (en) * 1990-09-07 1997-12-17 Schering Corporation Antiviral compounds and antihypertensive compounds
US5219864A (en) * 1991-03-12 1993-06-15 Kyowa Hakko Kogyo Co., Ltd. Thienopyridine derivatives
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
SE469368B (sv) 1991-10-09 1993-06-28 Kabi Pharmacia Ab Ny anvaendning av linomide foer tillverkning av laekemedel foer behandling av multiple sclerosis (ms)
TW222276B (https=) * 1992-01-27 1994-04-11 Fujisawa Pharmaceutical Co
SE9201076L (sv) * 1992-04-06 1993-10-07 Shimon Slavin Användningen av gamla läkemedel för behandling av diabetes
GB9311562D0 (en) * 1993-06-04 1993-07-21 Fujisawa Pharmaceutical Co Heterocyclic derivatives
SE9302490D0 (sv) * 1993-07-26 1993-07-26 Kabi Pharmacia Ab New use of old drugs
GB9404378D0 (en) * 1994-03-07 1994-04-20 Fujisawa Pharmaceutical Co Quinoline derivatives
SE9400810D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of Quinoline-3-carboxamide compounds
SE9400809D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of quinoline-3-carboxamide compounds
EP0841063A1 (en) * 1996-03-27 1998-05-13 Toray Industries, Inc. Ketone derivatives and medicinal use thereof
US5912349A (en) * 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
JPH1171351A (ja) * 1997-08-29 1999-03-16 Ss Pharmaceut Co Ltd 置換キノロン誘導体及びこれを含有する医薬
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802550D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
JP2000044560A (ja) * 1998-07-31 2000-02-15 Kyorin Pharmaceut Co Ltd ベンゾキノリジン誘導体及びその製造方法
JP2000044561A (ja) * 1998-07-31 2000-02-15 Kyorin Pharmaceut Co Ltd ピロロキノリン誘導体及びその製造方法
JP2000256323A (ja) 1999-01-08 2000-09-19 Japan Tobacco Inc ２−オキソキノリン化合物及びその医薬用途
RU2240313C2 (ru) * 1999-10-25 2004-11-20 Эктив Байотек Аб Лекарственные средства для лечения злокачественных опухолей
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
PL199781B1 (pl) 1999-10-25 2008-10-31 Active Biotech Ab Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania
AU1302301A (en) * 1999-11-08 2001-06-06 Sankyo Company Limited Nitrogenous heterocycle derivatives
US6525049B2 (en) 2000-07-05 2003-02-25 Pharmacia & Upjohn Company Pyrroloquinolones as antiviral agents
JP2003012667A (ja) * 2001-06-26 2003-01-15 Rrf Kenkyusho:Kk キノリンカルボキサミド骨格を有する抗菌剤
US6822097B1 (en) * 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
SE0201778D0 (sv) * 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US6875869B2 (en) * 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) * 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
WO2004104000A1 (ja) * 2003-05-23 2004-12-02 Japan Tobacco Inc. トリサイクリック縮合環化合物およびその医薬用途
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
WO2006002422A2 (en) 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
US7228698B2 (en) * 2005-06-30 2007-06-12 Premark Feg L.L.C. Refrigeration unit
WO2007038571A2 (en) * 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
NZ567088A (en) * 2005-10-19 2012-06-29 Teva Pharma Crystals of laquinimod sodium, and process for the manufacture thereof
EP1960363B1 (en) * 2005-12-09 2014-01-22 Amgen, Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions and uses thereof
WO2007124617A1 (fr) * 2006-04-28 2007-11-08 Institute Of Mataria Medica, Chinese Academy Of Medical Sciences Dérivés de coumarine, leurs procédés de préparation, compositions pharmaceutiques et utilisations
KR20150065951A (ko) * 2006-06-12 2015-06-15 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
EP2234485B1 (en) 2007-12-20 2013-11-13 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
WO2009133468A1 (en) * 2008-04-28 2009-11-05 Actavis Group Ptc Ehf Improved process for preparing quinoline-3-carboxamide derivatives
KR20110048571A (ko) * 2008-09-03 2011-05-11 테바 파마슈티컬 인더스트리즈 리미티드 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제
NZ592685A (en) 2008-10-23 2013-04-26 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
WO2010059549A1 (en) * 2008-11-18 2010-05-27 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
WO2010070449A2 (en) * 2008-12-17 2010-06-24 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
PL2458992T3 (pl) * 2009-07-30 2016-07-29 Teva Pharma Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu
WO2011019375A1 (en) * 2009-08-10 2011-02-17 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
SG183512A1 (en) * 2010-03-03 2012-09-27 Teva Pharma Treatment of lupus nephritis using laquinimod
DK2542079T3 (da) * 2010-03-03 2014-08-25 Teva Pharma Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat
CA2791711A1 (en) * 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of lupus arthritis using laquinimod
WO2012006538A1 (en) 2010-07-09 2012-01-12 Teva Pharmaceutical Industries Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
EP2590653A4 (en) * 2010-07-09 2014-01-01 Teva Pharma 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROCHINOLINE-3-CARBOXAMIDE, SALT THEREOF AND APPLICATIONS THEREOF
WO2012050500A1 (en) * 2010-10-14 2012-04-19 Lars Pettersson 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators.
FR2967498B1 (fr) * 2010-11-16 2015-01-02 Centre Nat Rech Scient Utilisation de derives de quinolinone comme outil de recherche
FR2967353B1 (fr) * 2010-11-16 2013-08-16 Centre Nat Rech Scient Derives de quinolinone
CA2851525A1 (en) 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
EP2780014A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CN104093310A (zh) 2012-02-03 2014-10-08 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
JP5989805B2 (ja) 2012-02-10 2016-09-07 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． メチル基変更酵素の調節物質、組成物及びその使用
JP6215238B2 (ja) 2012-02-16 2017-10-18 テバ ファーマシューティカル インダストリーズ リミティド Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
TW201350467A (zh) * 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
EP2916915A4 (en) 2012-11-07 2016-06-22 Teva Pharma LAQUINIMOD AMINE SALTS
US20160046582A1 (en) 2013-03-14 2016-02-18 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
WO2015168103A1 (en) 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
CN109843870A (zh) 2016-10-19 2019-06-04 星座制药公司 Ezh2抑制剂的合成
GB202006390D0 (en) 2020-04-30 2020-06-17 Aqilion Ab Novel treatments
CN115836056A (zh) * 2020-05-21 2023-03-21 Stemsynergy疗法有限责任公司 Notch抑制剂及其用途
CN111732540B (zh) * 2020-07-20 2020-11-13 湖南速博生物技术有限公司 一种罗喹美克的制备方法
AR126963A1 (es) 2021-09-13 2023-12-06 Lilly Co Eli Agonistas de ahr
TWI838849B (zh) 2021-09-13 2024-04-11 美商美國禮來大藥廠 Ahr促效劑
KR20250095720A (ko) 2022-10-31 2025-06-26 일라이 릴리 앤드 캄파니 Ahr 효능제
US20240199608A1 (en) * 2022-11-15 2024-06-20 Eli Lilly And Company Ahr agonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH471784A (de) * 1966-01-26 1969-04-30 Bayer Ag Verfahren zur Herstellung von Carbostyrilderivaten
US3524858A (en) * 1967-05-18 1970-08-18 Warner Lambert Pharmaceutical 1,4 - dihydro-1-substituted alkyl-6,7-methylenedioxy - 4 - oxoquinoline-3-carboxylic acid
CH578536A5 (en) 1973-05-11 1976-08-13 Ciba Geigy Ag Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props
CH578534A5 (en) 1973-05-11 1976-08-13 Ciba Geigy Ag Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props
CH578535A5 (en) 1973-05-11 1976-08-13 Ciba Geigy Ag Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props
CH578537A5 (en) 1973-05-11 1976-08-13 Ciba Geigy Ag Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props
CA1034124A (en) * 1973-05-11 1978-07-04 Ciba-Geigy Ag Process for the manufacture of new quinolines
US3917609A (en) * 1973-06-27 1975-11-04 Minnesota Mining & Mfg Pyrroloquinoline carboxylic acids and derivatives
FR2281761A1 (fr) * 1974-08-13 1976-03-12 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
FR2340735A1 (fr) 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
FR2482596A1 (fr) * 1980-05-19 1981-11-20 Roussel Uclaf Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur procede de preparation et leur application comme medicament
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation

Also Published As

Publication number Publication date
NO163130C (no) 1990-04-11
IE52670B1 (en) 1988-01-20
ATE15798T1 (de) 1985-10-15
ZA821210B (en) 1983-01-26
DE3266464D1 (en) 1985-10-31
HU186909B (en) 1985-10-28
IE820314L (en) 1982-09-03
NO820642L (no) 1982-09-06
EP0059698B1 (en) 1985-09-25
DK157859B (da) 1990-02-26
DK81282A (da) 1982-09-04
PH18520A (en) 1985-08-02
FI820728L (fi) 1982-09-04
AU547849B2 (en) 1985-11-07
IL65028A0 (en) 1982-04-30
PT74512A (en) 1982-04-01
NO163130B (no) 1990-01-02
US4547511A (en) 1985-10-15
NZ199888A (en) 1985-07-31
ES510042A0 (es) 1983-10-16
EP0059698A1 (en) 1982-09-08
JPH049786B2 (https=) 1992-02-21
US4738971A (en) 1988-04-19
HK38689A (en) 1989-05-19
PT74512B (en) 1983-11-08
AU8107682A (en) 1982-09-09
GR76073B (https=) 1984-08-03
FI79532C (fi) 1990-01-10
JPS57171975A (en) 1982-10-22
KR830009037A (ko) 1983-12-17
ES8400409A1 (es) 1983-10-16
IL65028A (en) 1986-11-30
DK157859C (da) 1990-07-30
CA1182455A (en) 1985-02-12
FI79532B (fi) 1989-09-29

Similar Documents

Publication Publication Date Title
KR860001876B1 (ko) 헤테로고리 카르복사미드의 제조방법
AU744518B2 (en) Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
CA1102802A (en) Benzothiazine derivatives
US4269846A (en) Heterocyclic compounds useful as anti-allergy agents
HU190408B (en) Process for producing pharmaceutical preparations comprising new benzimidazole-derivatives
NO151320B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktiv pyrrolidylmetyl-2-metoksy-4-amino-5-isopropyl-sulfonylbenzamider
US4299831A (en) 2-Trifluoromethyl-3-quinoline carboxamides, analgesic and anti-inflammatory compositions and methods employing them
NO147879B (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2-substituerte benzimidazoler
US4518775A (en) Benzoxazine-4-one intermediates
HU207053B (en) Process for producing cinnolinecarboxamide derivatives and pharmaceuitcal compositions comprising such compounds
KR0125938B1 (ko) 피리돈 카르복실산
JPS62147B2 (https=)
CA1218656A (en) Pyridothienotriazines
KR930003613B1 (ko) 술폰아미드 유도체의 제조방법
US5084456A (en) Oxazolopyridine compounds
US4390541A (en) Quinolone derivatives and their use in a method of controlling an immediate hypersensitivity disease
NZ238648A (en) Substituted benzoxazole derivatives and pharmaceutical compositions
EP0227431A1 (en) Heterocyclic amides
JP2566843B2 (ja) ベンゾチアジン誘導体、その製法、及び医薬品として又は医薬品の合成中間体としてのその適用
EP0790996B1 (en) Pyridazinoquinoline compounds
CS203934B2 (en) Process for preparing new derivatives of 1,3 thiazino/ /3,4-b/isoquinolines
KR810001502B1 (ko) 4-하이드록시-2h-1, 2-벤조티아진-3-카복스아미드-1, 1-디옥사이드의 제조방법
US3433794A (en) Certain 7 - (2 - aminophenyl) - 4,5 - dihydro thieno(2,3-c)pyridines and derivatives thereof
CA1094063A (en) Thieno ¬2,3-d| pyrimidine antiallergic agents
WO1983000863A1 (en) Antiinflammatory and analgetic 4-pyridylpyridazin(2h)-3-ones

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 13

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 19991025

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 19991025